No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial
Background . Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties . Human studies have proved its antiproteinuric effect in patients with glomerular diseases , but this study was design ed to assess the effects of add-on pentoxifylline to available treatment on reduction of microalbuminuria in diabetic patients without glomerular diseases . Methods . In a double-blind placebo-controlled , r and omized study we evaluated the influence of pentoxifylline on microalbuminuria in type 2 diabetic patients . 40 diabetic patients with estimated glomerular filtration rate ( eGFR ) of more than 60 mL/min/1.73 m2 in eight weeks and microalbuminuria were r and omized to two groups which will receive pentoxifylline 1200 mg/day or placebo added to regular medications for 6 months . albuminuria ; eGFR was evaluated at three- and six-month follow-up period . Results . Baseline characteristics were similar between the two groups . At six months , the mean estimated GFR and albuminuria were not different between two groups at 3- and 6-month follow-up . Trend of albumin to creatinine ratio , systolic and diastolic blood pressure , and eGFR in both groups were decreased , but no significant differences were noted between two groups ( P value > 0.05 ) . Conclusion . Pentoxifylline has not a significant additive antimicroalbuminuric effect compared with placebo in patients with type 2 diabetes with early stage of kidney disease ; however , further clinical investigations are necessary to be done
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .